8-K: Pulse Biosciences Completes $60 Million Rights Offering, Oversubscribed by 38%

Pulse Biosciences successfully closed its rights offering, raising $60 million with significant oversubscription, to support the development of its CellFX nsPFA technology.

Summary

• Pulse Biosciences has completed its rights offering, raising $60 million in gross proceeds.
• The offering was oversubscribed, with subscriptions exceeding $83 million, representing 138% of the target.
• The offering involved the sale of 6 million units at $10 per unit, each unit including one share of common stock and two warrants to purchase half a share of common stock at $11 per whole share.
• A total of 5,999,999 shares of common stock were issued, and warrants to acquire up to approximately 6 million additional shares were also issued.
• After the offering, the company has 61,228,332 shares of common stock issued and outstanding.
• The company intends to use the proceeds to support product and clinical development, regulatory submissions, and commercial readiness of its CellFX nsPFA products.

Sentiment

Score: 8

Explanation: The successful oversubscribed rights offering and the potential for additional funding through warrants indicate a positive outlook for the company's financial position and future growth.

Positives

• The rights offering was successfully completed, securing $60 million in funding.
• The offering was significantly oversubscribed, indicating strong investor interest.
• The funds will be used to advance the development and commercialization of the company's CellFX nsPFA technology.
• The inclusion of warrants provides potential for additional capital if exercised.
• The company's Executive Chairman, Robert Duggan, participated in the offering.

Risks

• The company's future success depends on the successful development and commercialization of its CellFX nsPFA technology.
• The company's actual results may differ materially from forward-looking statements due to various risks and uncertainties.
• The company's stock price may be volatile, and the warrants may not be exercised if the stock price does not reach the redemption thresholds.

Future Outlook

The company plans to use the proceeds from the offering to support further product and clinical development, future regulatory submissions, and commercial readiness of its three leading CellFX nsPFA products.

Management Comments

• The company is leveraging its novel and proprietary CellFX Nanosecond Pulsed Field Ablation (nsPFA) technology.
• The company is actively pursuing the development of its CellFX nsPFA technology for use in the treatment of atrial fibrillation and in a select few other markets.

Industry Context

This capital raise is crucial for Pulse Biosciences as it continues to develop its novel CellFX nsPFA technology, which is aimed at disrupting the bioelectric medicine space. The successful oversubscription indicates strong investor confidence in the company's technology and market potential.

Comparison to Industry Standards

• The oversubscription of the rights offering suggests a strong market interest in Pulse Biosciences' technology, which is a positive sign compared to other companies in the bioelectric medicine sector.
• The company's focus on non-thermal cell ablation is a differentiating factor compared to traditional thermal ablation methods used by competitors.
• The potential for $66 million in additional funding from warrant exercises provides a significant financial advantage compared to companies that rely solely on initial capital raises.

Stakeholder Impact

• Shareholders have the opportunity to benefit from the company's growth and potential stock price appreciation.
• Employees will benefit from the company's increased financial stability and growth prospects.
• Customers and patients may benefit from the development of new and improved medical treatments.
• Suppliers and creditors will benefit from the company's increased financial stability.

Next Steps

• The company will use the proceeds to support product and clinical development.
• The company will pursue future regulatory submissions.
• The company will focus on commercial readiness of its CellFX nsPFA products.
• The company will distribute shares, warrants and excess subscription payments on or about July 5, 2024.

Key Dates

Keywords

rights offering, CellFX nsPFA, capital raise, warrants, common stock, Pulse Biosciences, biotech, medical devices, funding, clinical development